Rosen Law Firm Urges Erasca, Inc. Investors to Join Securities Fraud Lawsuit

Rosen Law Firm, an international investor rights law firm, has urged purchasers of Erasca, Inc. (NASDAQ: ERAS) common stock to join a securities fraud lawsuit. Investors who bought shares between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek the role of lead plaintiff.

The lawsuit alleges that Erasca, Inc., along with its CEO and CFO, violated federal securities laws by making false and misleading statements regarding its lead oncology drug candidate, ERAS-0015, during the class period. According to the complaint, Erasca promoted ERAS-0015 as a potential "best-in-class" therapy and highlighted preclinical results compared to Revolution Medicines' competing drug candidate, RMC-6236. The suit claims these comparisons were improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis.

Investors who purchased Erasca stock during the specified period may be entitled to compensation without incurring out-of-pocket expenses through a contingency fee arrangement. Rosen Law Firm encourages investors to select counsel with a strong track record in securities class actions. The firm specializes in representing investors globally and has a history of securing substantial recoveries.

Interested investors can learn more by visiting the Rosen Law Firm's website or contacting them directly. While a class has not yet been certified, individuals have the option to retain counsel of their choice or remain an absent class member.